Is this TRALI, TACO, or just pneumonia? – a case report of acute respiratory failure

Pluta, Michał; Dziech, Magdalena; Jaworski, Tomasz; Krzych, Łukasz J.

doi:10.5114/ait.2019.90081

Cited by 2 publications

(3 citation statements)

References 5 publications

(6 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One may then expect that convalescent plasma should be the first choice of treatment [ 49 , 50 ], but recent data are not so convincing [ 51 ]. Moreover, plasma transfusion may have serious side effects, including transfusion-related immunomodulation and transfusion-related lung injury [ 52 ], which are of particular importance in COVID-19 patients with respiratory failure. Moreover, the time at which various biomarkers’ concentrations were measured was different between the studies.…”

Section: Limitationsmentioning

confidence: 99%

What Is the Role of Therapeutic Plasma Exchange as an Adjunctive Treatment in Severe COVID-19: A Systematic Review

Krzych

Putowski

Czok

et al. 2021

Viruses

View full text Add to dashboard Cite

Introduction: Since the COVID-19 pandemic outbreak, multiple promising treatment modalities have been tested, however, only several of them were proven to be effective. Therapeutic plasma exchange (TPE) has been recently discussed as a possible supportive treatment for severe cases. Methods: To investigate a possible role of TPE in severe COVID-19 we used a structured systematic search strategy to retrieve all relevant publications in the field. We screened in PubMed, EMBASE, Web of Science, Cochrane Library and clinicaltrials.gov for data published until the 4 June 2021. Results: We identified 18 papers, enrolling 384 patients, 220 of whom received TPE. The number of TPE sessions ranged from 1 to 9 and the type of replacement fluid varied markedly between studies (fresh frozen plasma or 5% albumin solution, or convalescent plasma). Biochemical improvement was observed in majority of studies as far as C-reactive protein (CRP), interleukin-6 (IL-6), ferritin, lactate dehydrogenase (LDH), D-dimer concentrations and lymphocyte count are concerned. The improvement at a laboratory level was associated with enhancement of respiratory function. Adverse effects were limited to five episodes of transient hypotension and one femoral artery puncture and thrombophlebitis. Conclusions: Although the effect of therapeutic plasma exchange on mortality remains unclarified, the procedure seems to improve various secondary end-points such as PaO2/FiO2 ratio or biomarkers of inflammation. Therapeutic plasma exchange appears to be a safe treatment modality in COVID-19 patients in terms of side effects.

show abstract

Section: Limitationsmentioning

confidence: 99%

What Is the Role of Therapeutic Plasma Exchange as an Adjunctive Treatment in Severe COVID-19: A Systematic Review

Krzych

Putowski

Czok

et al. 2021

Viruses

View full text Add to dashboard Cite

show abstract

“…De la misma forma la manipulación de los hemocomponentes, principalmente el lavado de glóbulos rojos consigue eliminar todos los mediadores implicados patogenia del TRALI, no obstante, estos procedimientos son caros, no se encuentran al alcance de todos los bancos de sangre y consumen una gran cantidad de tiempo, que no está disponible en la mayoría de los casos donde se necesite el hemocomponente de urgencia (5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17).…”

Section: Prevenciónunclassified

“…El mecanismo de acción propuesto, que hace que se desarrolle el cuadro clínico en TACO es una acumulación de fluido en la vasculatura pulmonar, lo que lleva a un aumento de la presión hidrostática y extravasación de fluido a los alveolos y tejidos(13).La neumonía, así como causas no infecciosas de edema pulmonar, entre las que figuran neumotórax, aspiración de contenido gástrico, embolismo pulmonar o hemorragia intra-alveolar también deben ser descartadas.Las reacciones inmunológicas inmunes, independientemente del historial médico del paciente también deben ser tomadas en cuenta al momento de hacer un posible diagnóstico diferencial(14).IncidenciaLa incidencia de este síndrome se ve afectada por el subregistro de casos, pues no se sospecha del mismo cuando se presenta(15). En Estados Unidos se presenta una incidencia de uno en cada 5000 transfusiones.…”

unclassified

Aspectos generales de Lesión Pulmonar aguda producida por transfusión sanguínea o TRALI.

Barquero¹

2022

View full text Add to dashboard Cite

TRALI o Lesión Pulmonar aguda producida por transfusión sanguínea es un síndrome clínico caracterizado por cursar con hipoxemia aguda y edema pulmonar (no cardiogénico) que ocurre durante o después de la transfusión de algún hemoderivado. Es una de las principales causantes de muerte relacionadas con una transfusión sanguínea. Adicionalmente ha sido clasificada en tipo I y II, donde la principal diferencia radica en que en el tipo II se incluyen pacientes con factores de riesgo para la aparición de SDRA. La investigación del cuadro permite manifestar que cualquier estado inflamatorio, sea cual sea la causa, cursa como el primer evento necesario para que se desarrolle el síndrome en estudio, y que el segundo evento involucrado, es la transfusión sanguínea.

show abstract

Is this TRALI, TACO, or just pneumonia? – a case report of acute respiratory failure

Cited by 2 publications

References 5 publications

What Is the Role of Therapeutic Plasma Exchange as an Adjunctive Treatment in Severe COVID-19: A Systematic Review

What Is the Role of Therapeutic Plasma Exchange as an Adjunctive Treatment in Severe COVID-19: A Systematic Review

Aspectos generales de Lesión Pulmonar aguda producida por transfusión sanguínea o TRALI.

Contact Info

Product

Resources

About